Brian Goodman, Ph.D.

Dr. Brian Goodman is a Partner at MPM and BioImpact Capital, an affiliate manager of MPM. He is responsible for investment identification, due diligence, business development and new company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Brian is a co-founder of Aktis Oncology and ReNAgade Therapeutics as well as a member of the Board of Directors of Orna Therapeutics.  He has also played key leadership roles at portfolio companies during the early stages of development, including at Orna Therapeutics and ReNAgade Therapeutics in Business Development and at Aktis Oncology as Chief Operations Officer.

Prior to joining MPM and BioImpact Capital, Brian co-founded Evelo Biosciences (NASDAQ: EVLO) and served as Head of Technology and Innovation. At Evelo, Brian led a team that established new programs to discover, formulate, and evaluate the pharmacology of microbial drugs across multiple therapeutic areas. He contributed to the in-licensing of foundational IP and forged collaborative research with multiple academic groups to complement Evelo’s internal research and development efforts. He is an inventor on multiple patent applications. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering where he worked with the entrepreneurial division to build and launch new biotech ventures.

Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.